Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
-
REGULATORY As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
-
REGULATORY Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
-
BUSINESS Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
-
REGULATORY Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
-
REGULATORY Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
ACADEMIA Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
-
BUSINESS LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
-
REGULATORY Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
-
BUSINESS Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
September 21, 2023
-
REGULATORY Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
-
REGULATORY MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
-
REGULATORY Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
-
ORGANIZATION JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
-
REGULATORY Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
-
REGULATORY New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
-
REGULATORY Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
-
REGULATORY Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
-
REGULATORY Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
-
REGULATORY Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
September 13, 2023
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…